Related Experiment Video
Updated: Jun 9, 2025
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.5K
PROTACs in platelets: emerging antithrombotic strategies and future perspectives
Justin S Trory1, Jordan Vautrinot, Carl J May
1School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Current Opinion in Hematology
|October 24, 2024
Summary
Proteolysis-targeted chimeras (PROTACs) can degrade proteins in anucleate platelets, offering new antithrombotic therapies. This approach shows potential for studying platelet function and treating thrombosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Proteolysis-targeted chimeras (PROTACs) are emerging therapeutics for diseases like cancer.
- PROTACs offer a novel approach to selectively degrade target proteins.
Purpose of the Study:
- To explore the application of PROTACs in anucleate platelets.
- To evaluate the antithrombotic potential of PROTACs in platelets.
Main Methods:
- Proteomic and biochemical analyses of human platelets.
- Application of cereblon (CRBN) ligand-based PROTACs targeting tyrosine kinases (Btk, Fak).
- Assessment of protein degradation and thrombus formation in vitro.
Main Results:
- Human platelets possess the Ubiquitin Proteasomal System and CRBN, making them susceptible to PROTACs.
- CRBN-based PROTACs effectively degraded target proteins like Btk in human platelets.
- Btk downregulation impaired in vitro thrombus formation without affecting hemostasis.
Conclusions:
- Platelets are susceptible to targeted protein degradation by PROTACs.
- The limited protein synthesis in platelets ensures sustained target downregulation.
- PROTACs are valuable tools for platelet research and hold therapeutic promise for antithrombotic strategies.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
478
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
478
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
625
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
01:29Venous Thrombosis III: Interprofessional Care
2
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
2
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:22Formation of the Platelet Plug
4.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.8K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154